There has been continuous research dedicated to the advancement of precision medicine and therapeutic strategies of surgical intervention and molecular research that impacts Genitourinary (GU) cancer patient outcome. GU cancer remains complex which leads to a variety of treatment for patients. Due to the improvements in medical care, the average life expectancy of patients affected by urological diseases has increased considerably in recent decades and therefore, technical innovations, new drugs and surgical methods are required to improve the prognosis.
The aim of this Research Topic is to provide information on the current and potential use of precision medicine in GU cancer. Early diagnosis is of crucial importance for the final clinical outcome. Previous studies have not identified a biomarker with sufficient sensitivity and specificity for the diagnosis of GU cancer. Identification of the target agents or the use of clinical collected data has brought significant benefits for patients in terms of early diagnosis.
Therefore, we collected clinical data and molecular biomarkers through “omics'' technologies with sufficient diagnostic specificity and sensitivity that are able to predict the clinical course of the disease and patient response to therapy. This Research Topic is aimed at summarizing the recent advances in preclinical and early drug developments regarding new treatment for various types of genitourinary cancer, with a special focus on clinical utility and how their implementation will lead to the growing personalization of genitourinary cancer care.
This Research Topic welcomes contributions related to both clinical surgical, precision medicine and basic research in the various genitourinary cancer spanning the following topics:
-Early diagnosis is of crucial importance for the final clinical outcome.
-Collected clinical data and molecular biomarker, through “omics” technologies with sufficient diagnostic specificity and sensitivity that are able to predict the clinical course of the disease, and patient response to therapy.
-Precision medicine in therapeutic approaches
-Development of epidemiological research on uro-oncology
-Clinical trials of new therapeutic agents developed
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
There has been continuous research dedicated to the advancement of precision medicine and therapeutic strategies of surgical intervention and molecular research that impacts Genitourinary (GU) cancer patient outcome. GU cancer remains complex which leads to a variety of treatment for patients. Due to the improvements in medical care, the average life expectancy of patients affected by urological diseases has increased considerably in recent decades and therefore, technical innovations, new drugs and surgical methods are required to improve the prognosis.
The aim of this Research Topic is to provide information on the current and potential use of precision medicine in GU cancer. Early diagnosis is of crucial importance for the final clinical outcome. Previous studies have not identified a biomarker with sufficient sensitivity and specificity for the diagnosis of GU cancer. Identification of the target agents or the use of clinical collected data has brought significant benefits for patients in terms of early diagnosis.
Therefore, we collected clinical data and molecular biomarkers through “omics'' technologies with sufficient diagnostic specificity and sensitivity that are able to predict the clinical course of the disease and patient response to therapy. This Research Topic is aimed at summarizing the recent advances in preclinical and early drug developments regarding new treatment for various types of genitourinary cancer, with a special focus on clinical utility and how their implementation will lead to the growing personalization of genitourinary cancer care.
This Research Topic welcomes contributions related to both clinical surgical, precision medicine and basic research in the various genitourinary cancer spanning the following topics:
-Early diagnosis is of crucial importance for the final clinical outcome.
-Collected clinical data and molecular biomarker, through “omics” technologies with sufficient diagnostic specificity and sensitivity that are able to predict the clinical course of the disease, and patient response to therapy.
-Precision medicine in therapeutic approaches
-Development of epidemiological research on uro-oncology
-Clinical trials of new therapeutic agents developed
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
